Can-Fite Reports Longer Overall Survival in Phase III Liver Cancer Study
RAMAT GAN, Israel, September 2, 2026 Can-Fite BioPharma Ltd. reported that blinded overall survival observed across the entire patient...
Phase III
Advertisement
Xentria Advances XTMAB-16 in Pulmonary Sarcoidosis
Chicago, Illinois, September 1, 2026 Xentria, Inc., a clinical-stage biotherapeutics company, has announced its next-stage clinical development plan for...
Novartis Remibrutinib Cuts Relapses in Phase III MS Trials
Basel, Switzerland, September 1, 2026 Novartis has announced positive topline results from the Phase III REMODEL-1 and REMODEL-2 trials,...
Kyowa Kirin Reaches U.S. Agreement to Lower Medicine Costs
TOKYO, Japan and PRINCETON, New Jersey, Aug. 31/Sept. 1, 2026 Kyowa Kirin Co., Ltd. announced a voluntary agreement with...
GSK Advances mRNA Flu Vaccine to Phase III After Data
LONDON, UK, Sept. 1, 2026 GSK announced that it will advance its investigational mRNA seasonal influenza vaccine candidate into...
Advertisements
HUTCHMED Reports Phase III SANOVO PFS Benefit in EGFR NSCLC
Hong Kong, Shanghai & Florham Park, NJ – August 31, 2026 HUTCHMED (China) Limited announced positive high-level results from...
Ipsen Completes Kartos Acquisition to Expand Oncology Pipeline
Paris, France | August 21, 2026 Ipsen announced the completion of its acquisition of Kartos Therapeutics, strengthening its late-stage...
GammaTile Shows Promise in Newly Diagnosed Glioblastoma
PROVIDENCE, R.I., August 18, 2026 GT Medical Technologies, Inc. announced new clinical findings suggesting that its GammaTile® targeted radiation...
HUTCHMED and AstraZeneca Advance ORPATHYS-TAGRISSO Lung Cancer Combination
Hong Kong, Shanghai & Florham Park, N.J., Aug. 17, 2026 HUTCHMED (China) Limited announced positive high-level results from the...
Pharming Launches Joenja in Japan for APDS Patients
LEIDEN, Netherlands, August 13, 2026 Pharming Group N.V. announced the commercial launch of Joenja® (leniolisib) in Japan for adults...
Advertisement
